Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
MUC5AC抗体(NPC-1C)联合二线吉西他滨和白蛋白紫杉醇治疗对晚期胰腺导管腺癌患者生存的影响:一项随机临床试验
期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2022.49720
Huffman, Brandon M; Basu Mallick, Atrayee; Horick, Nora K; Wang-Gillam, Andrea; Hosein, Peter Joel; Morse, Michael A; Beg, Muhammad Shaalan; Murphy, Janet E; Mavroukakis, Sharon; Zaki, Anjum; Schlechter, Benjamin L; Sanoff, Hanna; Manz, Christopher; Wolpin, Brian M; Arlen, Philip; Lacy, Jill; Cleary, James M